Trial Profile
Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 692342 (Primary) ; AS01B
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 18 Apr 2009 Actual patient number (181) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2009 Planned end date changed from 1 Feb 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.